Low let-7d exosomes from pulmonary vascular endothelial cells drive lung pericyte fibrosis through the TGFβRI/FoxM1/Smad/β-catenin pathway

Han Xie1,2 | Yuan-Mei Gao1 | Yong-Chang Zhang2 | Ming-Wang Jia1 | Fang Peng1 | Qing-He Meng3 | Yi-Chun Wang1

1Department of Critical Care Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
2Department of Lung Cancer and Gastroenterology, Hunan Cancer Hospital, Changsha, China
3Department of Surgery, SUNY Upstate Medical University, Syracuse, U.S.A

Correspondence
Yi-Chun Wang, Department of Critical Care Medicine, The Third Affiliated Hospital of Guangzhou Medical University, No. 63, Duobao Road, Guangzhou 510150, Guangdong Province, China.
Email: yichun4598@163.com

Funding information
Foundation of The Third Affiliated Hospital of Guangzhou Medical University, Grant/Award Number: 2019Z02; Hunan Provincial Natural Science Foundation of China, Grant/Award Number: 2018JJ2245

Abstract
The pathogenesis of pulmonary fibrosis (PF) was mediated by the progressive deposition of excessive extracellular matrix, but little is known about the regulatory mechanisms of fibrogenesis by lung pericytes. The mouse PF model was established by treatment with bleomycin, followed by isolation of exosomes from mouse broncho-alveolar lavage fluids by the centrifuge method. Relative mRNA/microRNA levels and protein expression were assessed by qRT-PCR and Western blotting, respectively. The binding of let-7d with gene promoter was validated by dual-luciferase reporter assay. Protein interactions were verified via GST pull-down and co-immunoprecipitation. Nuclear retention of Smad3 was analysed by extraction of cytoplasmic and nuclear fraction of pericytes followed by Western blotting. Association of FoxM1 with gene promoter was detected by EMSA and ChIP-PCR methods. FoxM1 expression is significantly elevated in human lung fibroblasts of PF patients and mouse PF model. The expression of let-7d is repressed in exosomes derived from broncho-alveolar lavage fluids of PF mice. Let-7d or FoxM1 knockdown suppressed the expression of FoxM1, Smad3, β-catenin, Col1A and α-SMA expression in mouse lung pericytes under TGF-β1 treatment. FoxM1 overexpression elevated above gene expression in mouse lung pericytes under TGF-β1 treatment. Let-7d directly targets TGFβRI to regulate FoxM1 and downstream gene expression in mouse lung pericytes. FoxM1 directly interacts with Smad3 proteins to promote Smad3 nuclear retention and binds with β-catenin promoter sequence to promote fibrogenesis. Exosomes with low let-7d from pulmonary vascular endothelial cells drive lung pericyte fibrosis through activating the TGFβRI/FoxM1/Smad/β-catenin signalling pathway.

KEYWORDS
exosomes, FoxM1, let-7d, lung pericyte fibrosis, TGFβRI, β-catenin
Pulmonary fibrosis (PF) is one severe interstitial lung disease featured by progressive deposition of excessive extracellular matrix (ECM) and lung tissue destruction with poor prognosis.¹⁻³ Based on etiology, PF could be categorized into the most common idiopathic pulmonary fibrosis (IPF) with no known causes and other subtypes caused by other disorders such as rheumatoid arthritis and scleroderma, genetic mutations or exposure to radiation and hazardous chemicals.⁴⁻⁵ The initiation and progression of PF have been known to be mediated by the alveolar epithelial cell activation, release of fibrogenic growth factors such as cytokines and growth factors, myofibroblast proliferation and activation, which resulted in abnormal ECM deposition and alterations.⁶ Nevertheless, the pathogenic mechanisms driving PF development are still far from being fully elucidated, which greatly hindered developing new therapeutic drugs for PF patients.

Pulmonary microvascular pericytes are responsible for generating collagen to maintain vascular stability in pulmonary vascular tissues by interacting with the epithelial cells under normal conditions.⁵ However, pulmonary microvascular pericytes could migrate to the pulmonary interstitium and transform into myofibroblasts expressing collagen, which has substantially contributed to the pathogenesis of PF.⁵⁻⁷ Recent investigations have demonstrated that TGF-β1 (transforming growth factor β1) and its receptor TGF-βRI (TGF-β receptor I) promoted the transformation of pericytes into myofibroblasts during PF pathogenesis, mediated by the activation of Smad2/3 (Smad and Mad homologue 2/3) signalling pathway.⁷ In addition, the β-catenin expression could also be up-regulated by TGF-β1 during the differentiation of lung pericytes into myofibroblasts.⁸ The activated Smad3 interacts with β-catenin to promote the expression of fibrosis iconic proteins including α-SMA, vimentin and collagen I (Col-I) during pericytes-to-myofibroblast transition and PF development.⁹ However, the mechanisms regulating the TGF-β1/ Smad3/β-catenin axis in PF pathogenesis remain poorly understood.

FoxM1 (Forkhead box M1) was originally characterized as a transcription factor regulating the expression of multiple functional genes associated with cell cycle progression.¹⁰⁻¹¹ Subsequent investigations revealed that FoxM1 served as a critical modulator of multiple other cellular processes such as cell proliferation and differentiation, apoptosis and DNA damage repair, thus promoting pathogenesis of human cancers and other disorders.¹⁰⁻¹² For instance, FoxM1 was identified as one downstream player of the Wnt/β-catenin signalling which directly binds with β-catenin to promote its nuclear localization and enhances the transcription factor activity of β-catenin during glioma development.¹²⁻¹⁴ Also, FoxM1 could directly promote the transcription of β-catenin to activate the re-annealing of endothelial adherent junctions during the repair of the injured vascular intima.¹⁵ In breast cancer cells, TIF1γ (transcriptional intermediary factor 1) is an E3 ubiquitin-protein ligase responsible for the ubiquitination-mediated degradation of Smad3/Smad4 protein complex, and FoxM1 protein could directly interact with the Smad3 proteins in the nucleus to inhibit the TIF1γ-mediated Smad4 protein degradation and maintain the sustained activation of the Smad3/Smad4 complex.¹⁶ Importantly, recent report showed that the elevated FoxM1 was required for the differentiation of pericytes into myofibroblasts in TGF-β1-elicited PF.¹⁷ However, little is known about the roles of FoxM1 and its interaction with the TGF-β1/Smad3/β-catenin signalling in pulmonary microvascular pericytes during PF pathogenesis.

Exosomes are a large group of critical membrane vesicles with a common diameter of 40 to 100 nanometres, which could be secreted by various cell types such as cancer cells and epithelial cells.¹⁸⁻¹⁹ Biochemically, exosomes are usually composed of multiple components including proteins, lipids, RNAs and small metabolites.²⁰ Although being originally considered as unwanted cell components, research in recent decades revealed that exosomes act as essential mediators of cellular signalling and intercellular communication because of their capability of carrying various bioactive macromolecules such as non-coding RNAs, which was substantially involved in pleiotropic biological and pathogenic processes.²¹⁻²² For instance, the miR-10b, which was highly expressed in breast cancer cells, could be secreted into extracellular region in exosomes to enhance the metastasis capacity of cancer cells.²³ The let-7 microRNA (miRNA) family was recently found to repress the pathogenesis of IPF associated with sex steroid hormones.²⁴ Also, let-7d is one member of the let-7 miRNA family and could inhibit the TGF-β1-induced epithelial-to-mesenchymal transition (EMT) during renal fibrogenesis by modulating the expression of signalling components downstream of TGF.²⁵ However, the roles of let-7d as well as its secretion in exosomes during PF development remain unclear.

In the present study, we aimed to test our hypothesis that exosomes carrying let-7d secreted by pulmonary vascular endothelial cells might improve pulmonary pericyte fibrosis, as well as the possible mechanism mediated by the TGF-βRI/FoxM1/Smad3/β-catenin signalling cascade. These results would characterize new biomarkers associated with PF pathogenesis and provide a basis for developing new anti-pulmonary fibrosis drugs.

2 | MATERIALS AND METHODS

2.1 | Clinical tissues and animal model

Human lung tissues were surgically collected from seven IPF patients registered to the Third Affiliated Hospital of Guangzhou Medical University (Guangzhou, China) and Hunan Cancer Hospital (Changsha, China) between December 2017 and March 2018. Lung tissues collected from seven healthy volunteers were used as negative control. The research was approved by the Medical Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University, and written consents were assigned by each participant before the surgery. The mouse pulmonary fibrosis model was established as previously introduced.⁶ Briefly, male C57/BL6 mice aged 8 weeks were purchased from Hunan SJA laboratory animal Co., LTD (Changsha, China) and sustained at 24 ± 2°C in autoclaved mouse...
cages with a 12-h light/dark cycle. Following anaesthetization with ketamine (25 mg/kg) dissolved in xylazine, mice were intratracheally injected with bleomycin sulphate solution (1.5 U/kg bodyweight) and killed for lung tissue collection and other assays 21 days later. Mice injected with the same volume of normal saline were used as the control group. The animal model establishment was approved by the Experimental Animal Care and Use Committee of the Third Affiliated Hospital of Guangzhou Medical University.

2.2 | Cell isolation and culture

The mouse lung microvascular endothelial line and mouse lung pericyte cell line were purchased from PriCells (Wuhan, China) and cultured in DMEM (Dulbecco's modified Eagle's medium) with supplementation of 10% foetal bovine serum (FBS) at 37°C in a humidified culture chamber with 5% CO₂. The mouse lung fibroblasts and human lung fibroblasts were isolated from the lung tissues collected from model mice or IPF patients, respectively, as previously described. Briefly, the lung tissues collected from C57/BL6 mice after designated treatments or IPF patients were immersed in Hank's balanced salt solution (#R0016; Beyotime, Beijing, China), following the instructions. Subsequently, 25 μg proteins of each group were boiled at 100°C for 5 minutes in protein loading buffer (#P0015; Beyotime, Beijing, China), separated by 10% or 12% SDS-PAGE and transferred onto PVDF membrane (Millipore). The PVDF with proteins was then blocked with 5% BSA solution (Beyotime, Beijing, China), separated by 10% or 12% SDS-PAGE and transferred onto PVDF membrane (Millipore). The PVDF with proteins was then blocked with 5% BSA solution (Sangon Biotech, Shanghai, China), followed by incubation with primary antibodies and HRP-conjugated secondary antibodies diluted in TBST. Finally, the expression of target proteins was detected by developing with the enhanced chemiluminescence (ECL) reagents (#32106; Thermo Fisher Scientific), with GAPDH or β-actin as the internal standard. Primary antibodies applied in this study include anti-FoxM1 (#5436, human; CST), anti-FoxM1 (ab180710, mouse; Abcam), anti-TGF-βRI (ab31013; Abcam), anti-Smad3 (ab40854; Abcam), anti-B-catenin (#ab480; CST), anti-β1 (ab34710; Abcam), anti-GAPDH (ab181602; Abcam) and FoxM1 expression in lung tissues as previously introduced. The immunohistochemistry (IHC) combined with haematoxylin and eosin (H&E) was performed to detect histological alteration and FoxM1 expression in lung tissues as previously introduced. Briefly, the lung tissues were fixed with 4% neutral phosphate-buffered formalin for 2 hours at room temperature, embedded in paraffin and made into 5-μm slides. Subsequently, tissues slides were blocked with 5% BSA solution (Beyotime, Beijing, China), incubated with diluted primary antibodies targeting FoxM1 (ab180710; Abcam; 1:500) for 1 hour at room temperature, incubated with HRP-conjugated secondary antibodies and developed with the DAB Substrate Kit (ab64238; Abcam), followed by staining with H&E.
histological alterations and protein expression in tissues were finally observed under microscopy. At least three biological repeats were accomplished.

2.7 | Exosome isolation and characterization

Following the establishment of the mouse pulmonary fibrosis model, the broncho-alveolar lavage fluids were collected from mice in the model group as well as the control group. The exosomes in broncho-alveolar lavage fluids were isolated as introduced previously.\(^2^6\) The diameters of exosomes isolated from mouse broncho-alveolar lavage fluids were then observed by electron microscopy (EM) method. Briefly, exosomes were fixed with 2% paraformaldehyde for 30 minutes at room temperature, loaded onto one copper-formvar/carbon-coated grids, followed by contrasting with 2% uranyl acetate, and finally observed by transmission electron microscope (JEOL 1010; 80 kV).

2.8 | Dual-luciferase reporter assay

To validate the direct binding of let-7d with TGFβRI gene promoter region, the dual-luciferase reporter assay was carried out using the pmirGLO Dual-Luciferase miRNA Target Expression Vector System (Promega). The recombinant pmirGLO-WT (wild-type) TGFβRI and pmirGLO-Mut (mutant) TGFβRI plasmids were established separately following the manufacturer’s instructions, which were then transfected into the mouse lung microvessel pericytes using the Lipofectamine 3000 reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions. The recombinant plasmids were transfected with the mixture of formaldehyde, 1× Buffer A and PBS for 12 minutes at room temperature, followed by incubation with the mixture of formaldehyde, 1× Buffer A and PBS for 12 minutes at room temperature, loaded onto one copper-formvar/carbon-coated grids, followed by contrasting with 2% uranyl acetate, and finally observed by transmission electron microscope (JEOL 1010; 80 kV).

2.10 | Electrophoretic mobility shift assay (EMSA)

The direct binding of FoxM1 protein with the promoter sequences of the β-catenin gene was confirmed in vitro by EMSA using the LightShift™ Chemiluminescent EMSA Kit (#20148; Thermo Fisher Scientific) following the manufacturer’s instructions. Briefly, the DNA target sequences of the β-catenin gene used as the native probe, as well as the mutant probe, were biotinylated using the Biotin 3’ End DNA Labeling Kit (#89818; Thermo Fisher Scientific) according to the manufacturer’s instructions. Subsequently, the native probe was incubated with the FoxM1 proteins or in combination with anti-FoxM1 antibodies, followed by Western blotting using primary antibodies targeting biotin. Also, the mutant probe incubated with the FoxM1 proteins was applied as the negative control.

2.11 | Chromatin Immunoprecipitation (ChIP)

The validation of FoxM1 protein binding with β-catenin gene promoter region in mouse lung pericytes by ChIP was finished using the ChIP Kit (#ab500; Abcam) following protocol provided by the manufacturer. Briefly, the cultured lung pericytes were first fixed with the mixture of formaldehyde, 1× Buffer A and PBS for 12 minutes at room temperature, followed by incubation with the Buffer B for 15 minutes at room temperature, incubation with Buffer C for 12 minutes at room temperature and incubation with the mixture of Buffer D and PI for 15 minutes at room temperature. The optimal DNA fragmentation was induced by appropriate sonication of the above cell mixture, which was subjected to centrifuge at 14,000 g for 10 minutes at 4°C. The resultant supernatant containing DNA fragments was immunoprecipitated with the antibodies targeting the FoxM1 proteins, and the bound DNAs were subsequently purified using the DNA purifying slurry. Finally, the existence of β-catenin gene promoter sequences of interest was detected by the PCR method. DNA fragments precipitated with anti-IgG antibodies were used as the negative control.

2.12 | Statistical analysis

The SPSS 22.0 software was used to test the significance of quantitative data presented as mean ± SD (standard deviation) based on at least three biological replicates. The differences between two or more groups were analysed by the Student’s t test and the ANOVA (analysis of variance) methods, respectively. The significant differences were defined by P < .05.
3 RESULTS

3.1 Elevated FoxM1 expression in IPF patients and mouse models

To investigate the potential involvement of FoxM1 during IPF pathogenesis, we first isolated the lung fibroblasts from clinical tissues collected from eight patients diagnosed with IPF, and fibroblasts from healthy volunteers were used as the negative group. Through qRT-PCR, we showed that the FoxM1 mRNA levels in lung fibroblasts from IPF patients were significantly higher than those of the normal group (Figure 1A). Also, the increased expression of FoxM1 in lung fibroblasts isolated from IPF patients was further confirmed by our following Western blotting assay (Figure 1B). Moreover, we analysed the histological alterations of lung tissues in IPF patients and observed significant fibrosis and disordered structure in the lung tissues of IPF patients, in comparison with those of the normal group (Figure 1C). In consistence, we found by IHC analysis that the expression of FoxM1 proteins in the lung tissues of IPF patients was also greatly higher than that in those of the normal group (Figure 1C). Next, we established the mouse pulmonary fibrosis model by treatment with bleomycin as introduced in the Material and Methods section. Through qRT-PCR, Western blotting and IHC methods, we showed that the FoxM1 expression in the lung tissues of mouse model was remarkably elevated compared with the control group (treated with saline; Figure 1D-F). Significant tissue fibrosis was also observed in the lung tissues of the mouse model, but not in the control group (Figure 1F). These results showed the significantly increased FoxM1 expression in lung tissues during PF pathogenesis.

**FIGURE 1** Significant increase in FoxM1 gene expression associated with pulmonary fibrosis. A and B, The expression of FoxM1 in lung fibroblasts isolated from lung tissues of IPF patients. FoxM1 mRNA and protein levels in fibroblasts were detected by qRT-PCR (A) and Western blotting (B). C, Histological evaluations of lung tissues collected from IPF patients. The histological alteration of lung tissues was observed following H&E staining, and FoxM1 protein abundances in lung tissues were analysed by IHC assay. D and E, The increased expression level of FoxM1 in lung tissues from mouse pulmonary fibrosis model. The mice were treated with bleomycin sulphate solution (1.5 U/kg bodyweight) or the same volume of normal saline by intratracheal injection. FoxM1 mRNA and protein levels in mouse lung tissues were measured by qRT-PCR (D) and Western blotting (E). F, Histological features and FoxM1 protein expression in the lung tissues of pulmonary fibrosis model mice. Lung tissues from mice were analysed by H&E and IHC assays. IPF: idiopathic pulmonary fibrosis; FoxM1: Forkhead box M1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; *P < .05; **P < .01.
3.2 Decreased let-7d in exosomes and increased FoxM1 expression from mouse PF model

For analysis of the roles of exosomes in pathogenesis of PF, we then isolated the exosomes from broncho-alveolar lavage fluids of the mouse PF model as well as the normal control group, as described in the Material and Methods section. Our following TEM analysis showed that exosomes from mouse broncho-alveolar lavage fluids had a diameter of 30-100 nm, which was consistent with previous reports (Figure 2A). Also, we observed the expression of let-7d in exosomes isolated from both the control group and PF model, and significant decrease of let-7d expression in the model group compared with the control group (Figure 2B). On the contrary, our following Western blotting assay also showed that FoxM1 protein expression in mouse lung pericytes treated with exosomes from PF model mice was markedly higher than that of the control group (Figure 2C). Furthermore, we also found that the expression of key signalling components and fibrosis-related genes in mouse lung pericytes was greatly increased by exosomes from model mice compared with those treated with exosomes from the control group, including Smad3, β-catenin, Col1A and α-SMA (Figure 2C). These results indicated the roles of exosomes with low let-7d and pericytes with high FoxM1 expression in regulating PF pathogenesis.

3.3 Let-7d mitigated FoxM1-promoted expression of Smad3, β-catenin and fibrosis-related genes in mouse lung pericytes under TGF-β1 treatment

To further investigate the effects of FoxM1 and let-7d in regulating PF development, we then analysed the expression of FoxM1 and
downstream signalling and fibrosis-related genes in mouse pericytes treated with TGF-β1 by Western blotting. We found that the TGF-β1 treatment significantly elevated the protein levels of FoxM1 in mouse pericytes compared with the control group (Figure 3A). Also, the protein levels of Smad3, β-catenin, Col1A and α-SMA in mouse pericytes were all significantly increased by TGF-β1 treatment compared with the control group (Figure 3A). Under TGF-β1 treatment, the overexpression of FoxM1 caused much more significant increase of FoxM1 expression in mouse pericytes in comparison with the control group, as well as remarkable increases of...
Smad3, β-catenin, Col1A and α-SMA expression (Figure 3A). On the contrary, the knockdown of FoxM1 expression with specific shRNA targeting FoxM1 (shFoxM1) effectively suppressed the increases of FoxM1, Smad3, β-catenin, Col1A and α-SMA expression in mouse pericytes induced by TGF-β1 treatment (Figure 3A). To assess the effect of exosomes derived from normal or PF model (Ctrl-exos or Model-exos) on FoxM1, Smad3, β-catenin, Col1A and α-SMA expression in pericytes, the primary cultured pericytes were treated with exosomes for 48 hours, and we found that the treatment with Model-exos including low let-7d remarkably up-regulated the expression of FoxM1, Smad3, β-catenin, Col1A and α-SMA proteins in mouse pericytes under TGF-β1 treatment or combined with FoxM1 overexpression or knockdown (Figure 3B). These results showed that the elevation of FoxM1 and downstream signalling component expression in mouse lung pericytes could be repressed by let-7d.

3.4 | Let-7d targets TGFβRI to suppress FoxM1 and downstream gene expression in mouse lung pericytes

For more insights into the downstream target of let-7d in lung pericytes during PF development, we then performed a bioinformatic analysis and showed that let-7d might directly bind with the promoter region of the TGFβRI (Figure 4A). Moreover, we found that treatment with let-7d mimic significantly elevated let-7d expression but suppressed TGFβRI expression in mouse pericytes compared with the negative control (NC) group (Figure 4B). Contrarily, the treatment with let-7d inhibitor effectively repressed let-7d expression in mouse pericytes, which caused greatly elevated expression of TGFβRI in mouse lung pericytes compared with the negative control group (Figure 4B). Through dual-luciferase reporter assay, we showed that the let-7d induced significant decrease of luciferase activity in mouse lung pericytes expressing the wild-type TGFβRI 3’ un-translated region (3’UTR) sequences, but not in the pericytes expressing the mutant TGFβRI 3’UTR sequences, showing the direct binding of let-7d with the 3’UTR of TGFβRI (Figure 4C). Subsequently, we showed that let-7d mimic remarkably down-regulated the expression of TGFβRI, FoxM1, Smad3, Col1A and α-SMA in mouse lung pericytes compared with the NC group (Figure 4D). On the contrary, the let-7d inhibitor caused significant increase of these genes in mouse lung pericytes in comparison with the NC group (Figure 4D). These results showed that let-7d could suppress the expression of FoxM1 and downstream signalling and fibrosis-related genes in lung pericytes by directly targeting TGFβRI.
3.5 | FoxM1 interacts with Smad3 protein to promote nuclear retention of Smad3 proteins in lung pericytes

To study the molecular mechanisms of FoxM1 functioning in PF, we first test the possibility of direct interaction between FoxM1 and Smad3. Through pull-down assay, we showed that FoxM1 protein could be effectively pulled down together with GST (glutathione S-transferase)-tagged Smad3 proteins, showing the direct interaction of FoxM1 proteins with the Smad3 proteins in vitro (Figure 5A). Our following Co-IP assay also showed that endogenous FoxM1 protein could directly associate with Smad3 proteins in mouse lung pericytes (Figure 5B). Also, the treatment of TGF-β1 effectively enhanced the association of endogenous FoxM1 proteins with Smad3
proteins in mouse lung pericytes, as well as the interaction of FoxM1 proteins with phosphorylated Smad3 proteins (Figure 5B). Through separate purification of the cytosol and nuclear fractions of mouse lung pericytes combined with Western blotting, we showed that TGF-β1 treatment significantly increased the Smad3 protein levels in the nuclear fractions of mouse lung pericytes, together with decrease of Smad3 in cytoplasmatic fractions of mouse lung pericytes treated with TGF-β1 (Figure 5C). Moreover, we found that the Smad3 protein levels in nuclear fractions of mouse lung pericytes under TGF-β1 treatment could be further elevated by overexpression of FoxM1 (Figure 5C). The nuclear Smad3 protein levels in mouse lung pericytes under TGF-β1 treatment were also shown to be reduced by the treatment with TGFβRI inhibitor SB431542 in a concentration-dependent manner (Figure 5C). Furthermore, we showed that the knockdown of FoxM1 with shFoxM1 significantly reduced the nuclear FoxM1 levels in mouse lung pericytes (Figure 5D). In addition, the increased nuclear Smad3 protein level in mouse lung pericytes under TGF-β1 treatment was also greatly down-regulated by shFoxM1 transfection (Figure 5D). These results showed that FoxM1 could directly associate with Smad3 proteins to promote the TGF-β1-induced nuclear retention of Smad3 proteins in mouse lung pericytes.

3.6 | FoxM1 attenuates TIF1γ-mediated Smad4 protein ubiquitination and TGF-β1 signalling inhibition in mouse lung pericytes

To further investigate the molecular events downstream of FoxM1 in PF pathogenesis, we then analysed the involvement of TIF1γ-induced inhibition of Smad3/4 functions as transcription factor. Using the Smad4-responsive SBE4-Luc reporter gene, we found that TGF-β1 treatment enhanced the luciferase activity of the SBE4-Luc reporter gene in mouse lung pericyte, which could be significantly inhibited by the overexpression of the TIF1γ, showing the inhibition of TIF1γ on the Smad3/4-mediated downstream gene transcription (Figure 6A). However, the inhibition of Smad3/4-mediated transcription by TIF1γ in mouse lung pericytes under TGF-β1 treatment could be partially attenuated by FoxM1 overexpression (Figure 6A). Also, the formation of Smad3/4 protein complex in lung pericytes caused by TGF-β1 treatment could be inhibited by TIF1γ overexpression, but FoxM1 overexpression significantly relieved the inhibition of formation of Smad3/4 protein complex by TIF1γ (Figure 6B). Moreover, we observed that the interaction of TIF1γ with Smad4 as well as the mono-ubiquitination of Smad4 protein in mouse lung pericytes under TGF-β1 treatment was also remarkably suppressed by FoxM1 overexpression (Figure 6C and D). Furthermore, the interaction of TIF1γ and Smad4 in mouse lung pericytes was greatly repressed by the knockdown of Smad3 expression using siRNAs targeting Smad3 (Figure 6E). In addition, our co-immunoprecipitation also confirmed that FoxM1 overexpression repressed the direct binding of Smad3 with TIF1γ in mouse lung pericytes (Figure 6F). Together, these results showed that FoxM1 promoted the expression of TGF-β1 signalling through attenuating the TIF1γ-induced Smad4 protein ubiquitination.

3.7 | Smad3 interacts with β-catenin, and FoxM1 binds with β-catenin promoter to enhance fibrosis gene expression in mouse lung pericytes

For more insights into the regulation of fibrosis by FoxM1 and Smad3, we finally tested the potential roles of FoxM1 and Smad3 in regulating β-catenin gene expression as transcription factor. We showed that transfection with shRNAs targeting β-catenin significantly repressed the expression of Col1A and α-SMA in mouse lung pericytes under treatments with TGF-β1 and let-7d (Figure 7A). Also, the expression of Col1A and α-SMA in mouse lung pericytes treated with TGF-β1 and let-7d was remarkably repressed by the treatment with SB431542 (Figure 7B). The knockdown of FoxM1 by shFoxM1 induced significant decrease of β-catenin expression in mouse lung pericytes (Figure 7C). Our following EMSA assay showed that FoxM1 protein could directly bind with the promoter region of the β-catenin (Figure 7D). Through ChIP assay combined with PCR, we showed that the association of FoxM1 protein with the promoter region of the β-catenin was significantly repressed by the transfection with shFoxM1 in mouse lung pericytes (Figure 7E). These results showed that Smad3 interacts with β-catenin to regulate the expression of downstream genes involved in lung fibrosis, and FoxM1 could bind with the promoter of β-catenin to modulate fibrosis-related gene expression in mouse lung pericytes.
The pathogenesis of pulmonary fibrosis (PF) has long been known to closely link with the differentiation of pulmonary microvascular pericytes into myofibroblasts and abnormal deposition of extracellular matrix, which was mediated by the alterations of the TGF-β1/Smad3/β-catenin signalling cascade; however, the regulatory mechanisms of this signalling axis during pericyte transformation and fibrosis remain poorly understood. In the present study, we showed that FoxM1 protein, one transcription factor previously known to substantially regulate cell proliferation and cell cycle, was highly expressed in lung fibroblasts during PF pathogenesis. On the contrary, the expression of one microRNA let-7a was greatly down-regulated in exosomes from broncho-alveolar lavage fluid of mouse PF model. Our following assays proved that FoxM1 overexpression could promote the expression of Smad3, β-catenin, Col1A and α-SMA genes in mouse lung pericytes, whereas overexpression of let-7d then significantly repressed the expression of these genes in mouse lung pericytes. Moreover, we subsequently revealed that let-7d performed its roles of regulating fibrosis-related signalling pathways and gene expression in lung pericytes by directly targeting and suppressing TGFβRI. Meanwhile, FoxM1 was found in this study to enhance the nuclear

**Figure 7** Smad3 interacts with β-catenin and FoxM1 binds with β-catenin promoter to enhance fibrosis gene expression in mouse lung pericytes. A and B, The expression of β-catenin, Col1A and α-SMA in mouse lung pericytes treated with TGF-β1, SB431542 and shβ-catenin. Pericytes transfected with the indicated sequences were treated with TGF-β1 (5 ng/mL) and SB431542 (3 μmol/L) for 2 h. Fibrosis-related gene expression was evaluated by Western blotting, using β-actin as the internal standard. C, The abundances of FoxM1 and β-catenin proteins in mouse lung pericytes transfected with shFoxM1. Protein levels were measured by Western blotting. D, The direct binding of FoxM1 proteins with the promoter regions of the β-catenin gene. Association of FoxM1 with β-catenin promoter regions was validated by the EMSA method. E, Influence of the FoxM1 knockdown on the association of FoxM1 protein with the promoter regions of β-catenin. The association of FoxM1 protein with promoter sequences was measured by the ChIP method followed by PCR. TGF-β1: transforming growth factor beta1; NC: negative control; shβ-catenin: shRNAs targeting β-catenin; Col1A: collagen Iα; α-SMA: α-smooth muscle actin; FoxM1: Forkhead box M1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; *P < .05; **P < .01
retention of Smad3 proteins and prevent the TIF1γ-mediated mono-ubiquitination and degradation of Smad3 proteins through directly binding with Smad4 proteins. Furthermore, FoxM1 could also associate with the promoter region of the β-catenin to regulate expression of fibrosis-related genes in lung pericytes. These results disclosed a new TGF-βRI/FoxM1/Smad/β-catenin axis in lung pericytes, which could be negatively regulated by let-7d in exosomes from pulmonary vascular endothelial cells, in mediating PF pathogenesis.

Non-coding RNAs such as microRNAs (miRNAs), circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) have been established as essential mediators of human diseases in the past decades. Among them, microRNAs serve as potent regulator of gene expression via directly binding with the 3' UTR region of functional genes, thus being reported to be widely involved in pathogenic processes of various human diseases including idiopathic pulmonary fibrosis (IPF). On the other hand, microRNAs have also been characterized as one major group of cargos that could be transferred by exosomes to exert physiological and pathogenic functions in tissues away from its original sites. However, litter is recently known about the roles of microRNAs encapsulated in exosomes secreted by pulmonary vascular endothelial cells in regulating lung pericyte fibrosis. In this study, we found that the expression of let-7d, a microRNA previously known to suppress TGF-β1-induced renal fibrogenesis, was significantly reduced in exosomes from mouse PF model. Importantly, the expression of Smad3 and β-catenin in mouse lung pericytes, as well as Col1A and α-SMA involved in fibrosis, was significantly repressed by overexpression of let-7d, but elevated by treatment with these low let-7d isolated from model mice compared with exosomes from normal mice. More importantly, we proved here that let-7d could directly target the TGFβRI in mouse pericytes, which indicated that the modulation of TGFβRI expression by non-coding RNAs might serve as a promising strategy to prevent PF pathogenesis.

FoxM1 (Forkhead box M1) was previously reported as an essential regulator of the Wnt/β-catenin signalling pathway through directly binding with β-catenin protein to retain β-catenin in nucleus and promoting the β-catenin transcription. Also, FoxM1 could enhance the TGF-β1/Smad3 signalling in cancer cells by stabilizing Smad3/Smad4 complex and inhibiting Smad4 protein degradation induced by TIF1γ. Here, in the present study, we showed that FoxM1 expression was highly elevated in the lung fibroblasts in mouse model and human tissues with PF. Moreover, the expression of FoxM1 gene in mouse lung pericytes could be enhanced by TGF-β1 treatment and let-7d inhibitor, but effectively down-regulated by let-7d mimics. Of significance, we showed here that FoxM1 overexpression in mouse lung pericytes significantly elevated the expression of Smad3, β-catenin, Col1A and α-SMA, whose expression could also be repressed by FoxM1 knockdown in mouse lung pericytes under TGF-β1 treatment. These results convincingly supported the roles of FoxM1 as a key positive mediator of TGF-β1/Smad3/β-catenin signalling during PF pathogenesis, which is consistent with previous report showing the association of FoxM1 with transformation of lung pericytes into myofibroblasts. In terms of molecular mechanisms, we showed in this study that the FoxM1 could directly associate with the Smad3 protein, which resulted in greatly increased Smad3 nuclear retention and promoted expression of downstream genes. Furthermore, we also showed that the mono-ubiquitination and degradation of Smad4, which was induced by TIF1γ, could be inhibited by the binding of FoxM1 protein with Smad3 protein. Together, our above-mentioned findings in this study indicated that the regulation of Smad3/4 protein complex stability and Smad3 nuclear retention might be a prevalent molecular mechanism of FoxM1 functioning in distinct physiological and pathogenic contexts.

As introduced above, the regulation of β-catenin transcription and nuclear distribution by FoxM1 protein was critically associated with the TGF-β1 signalling cascade. Previous report proved that β-catenin serves as one important co-factor of the TCF (T-cell factor) transcription factors, which could mediate various biological processes by promoting the expression of a multitude of downstream functional genes such as cyclin-D1, c-myc and survivin. The activation of β-catenin signalling has been suggested as a common feature of lung fibrosis, because of its potent roles of promoting pulmonary fibroblast proliferation and migration. In this study, we showed the expression of β-catenin in mouse lung pericytes was significantly increased by TGF-β1 treatment, let-7d inhibitor and FoxM1 overexpression, but greatly repressed by let-7d mimic, TGFβRI inhibitor and FoxM1 knockdown. Also, β-catenin knockdown with shRNAs caused significant decreases of Col1A and α-SMA expression in mouse lung pericytes under TGF-β1 treatment. Importantly, we finally showed that FoxM1 proteins could be directly associated with promoter region of the β-catenin in mouse lung pericytes by both EMSA and ChIP-PCR assays, which validated the roles of β-catenin in PF development, as well as the diversity of molecular mechanisms underlying FoxM1 and β-catenin-mediated lung pericyte fibrosis.

5 | CONCLUSIONS

In summary, we unveiled in this study that the microRNA let-7d, whose expression was suppressed in exosomes derived from pulmonary vascular endothelial cells, could target and repress the TGFβRI to modulate the downstream FoxM1/Smad/β-catenin signalling axis and lung pericyte fibrosis. FoxM1 protein could enhance the nuclear retention of Smad3 protein and stabilize Smad3/4 protein complex to promote the expression of fibrotic gene expression in lung pericytes by directly binding with Smad3 protein. These results provided novel insights into the pathogenesis of PF mediated by the TGF-β1/Smad and Wnt/β-catenin signalling cascades, which might serve as a basis for developing new drugs preventing PF development.

ACKNOWLEDGEMENTS

This study was supported by grants from Hunan Provincial Natural Science Foundation of China (No. 2018JJ2245) and Foundation of The Third Affiliated Hospital of Guangzhou Medical University (No. 2019Z02).

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.
AUTHOR CONTRIBUTIONS
Han Xie: Resources (equal). Yuan-Mei Gao: Writing-review & editing (equal). Yong-Chang Zhang: Resources (equal). Ming-Wang Jia: Writing-original draft (equal). Fang Peng: Resources (equal). Qing-He Meng: Writing-review & editing (equal). Yi-Chun Wang: Writing-review & editing (equal).

ETHICAL APPROVAL
The research was approved by the Medical Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University, and written consents were assigned by each participant before the surgery.

DATA AVAILABILITY STATEMENT
All data generated or analyzed during this study are included in this published article.

ORCID
Yi-Chun Wang https://orcid.org/0000-0001-7507-6753

REFERENCES
1. Glasser SW, Hagood JS, Wong S, Taye CA, Madala SK, Hardie WD. Mechanisms of lung fibrosis resolution. Am J Pathol. 2016;186:1066-1077.
2. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389:1941-1952.
3. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132:1311-1321.
4. Yoshida T, Ohnuma A, Horiiuchi H, Harada T. Pulmonary fibrosis in response to environmental cues and molecular targets involved in its pathogenesis. J Toxicol Pathol. 2011;24:9-24.
5. Harrell CR, Simovic Markovic B, Fellabaum C, Arsenijevic A, Djonov V, Volarevic V. Molecular mechanisms underlying therapeutic potential of pericytes. J Biomed Sci. 2018;25:21.
6. Sava P, Ramanathan A, Dobronyi A, Peng X, Gonzalez AL. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung. JCI Insight. 2017;2(24):e96352
7. Sun W, Tang H, Gao L, et al. Mechanisms of pulmonary fibrosis induced by core fucosylation in pericytes. Int J Biochem Cell Biol. 2017;88:44-54.
8. Li J, Wang G, Sun X. Transforming growth factor beta regulates beta-catenin expression in lung fibroblast through NF-kappaB dependent pathway. Int J Mol Med. 2014;34:1219-1224.
9. Xu L, Cui W-H, Zhou W-C, et al. Activation of Wnt/β-catenin signaling is required for TGF-β1/Md5 signalling during myofibroblast proliferation. J Cell Mol Med. 2017;21:1545-1554.
10. Halasi M, Gartel AL. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle. 2009;8:1966-1967.
11. Laura B, Stefania Z, de Moraes GN, Eric W-F. FoxM1: A key onco-fetal transcription factor in health and disease. Semin Cancer Biol. 2014;29:8.
12. Koo CY, Muir KW, Lam EW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta. 2012;1819:28-37.
13. Bowman A, Nusse R. Location, location, location: FoxM1 mediates beta-catenin nuclear translocation and promotes glioma tumorigenesis. Cancer Cell. 2011;20:415-416.
14. Zhang N, Wei P, Gong A, et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 2011;20:427-442.
15. Mirza MK, Sun Y, Zhao YD, et al. FoxM1 regulates re-annealing of endothelial adherens junctions through transcriptional control of β-catenin expression. J Exp Med. 2010;207:1675-1685.
16. Xue J, Lin X, Chiu W-T, et al. Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. Journal of Clinical Investigation. 2014;124:554-579.
17. Penke LR, Speth JM, Dommeti VL, White ES, Bergin IL, Peters-Golden M. FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis. J Clin Invest. 2018;128:2389-2405.
18. Meng W, Hao Y, He C, Li L, Zhu G. Exosome-orchestrated hypoxic tumor microenvironment. Mol Cancer. 2019;18:57.
19. Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-mediated metastasis: communication from a distance. Dev Cell. 2019;49:347-360.
20. Butler JS. The Yin and Yang of the Exosome. Trends Cell Biol. 2002;12:90-96.
21. Kita S, Maeda N, Shimomura I. Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J Clin Invest. 2019;129:4041-4049.
22. Vyas N, Dhawan J. Exosomes: mobile platforms for targeted and synergistic signaling across cell boundaries. Cell Mol Life Sci. 2017;74:1567-1576.
23. Singh R, Pochampally R, Watabe K, Lu Z, Mo YY. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer. 2014;13:256.
24. Elliot S, Periera-Simon S, Xia X, et al. MicroRNA let-7 downregulates ligand-independent estrogen receptor-mediated male-predominant pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200:1246-1257.
25. Wang Y, Le Y, Xue JY, Zheng ZJ, Xue YM. Let-7d miRNA prevents TGF-beta1-induced EMT and renal fibrogenesis through regulation of HMGA2 expression. Biochem Biophys Res Comm. 2016;479:676-682.
26. Carnino JM, Lee H, Jin Y. Isolation and characterization of extracellular vesicles from Broncho-alveolar lavage fluid: a review and comparison of different methods. Respir Res. 2019;20:240.
27. de Almeida RA, Fraczek MG, Parker S, Delneri D, O’Keefe RT. Non-coding RNAs and disease: the classical ncRNAs make a comeback. Biochem Soc Trans. 2016;44:1073-1078.
28. Nothnick WB. Non-coding RNAs in uterine development, function and disease. Adv Exp Med Biol. 2016;886:171-189.
29. Chen X, Xie D, Zhao Q, You ZH. MicroRNAs and complex diseases: from experimental results to computational models. Brief Bioinform. 2017;18:558.
30. Li H, Zhao X, Shan H, Liang H. MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics. Acta Pharm Sin B. 2016;6:531-539.
31. Mizuno K, Matakii H, Seki N, Kumamoto T, Kamikawaji K, Inoue H. MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis. J Hum Genet. 2016;62:57-65.
32. Quinlan S, Kenny A, Medina M, Engel T, Jimenez-Mateos EM. MicroRNAs in neurodegenerative diseases. Int Rev Cell Mol Biol. 2017;334:309.
33. Lee JM, Yang J, Newell P, et al. beta-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett. 2014;343:90-97.
34. Lam AP, Flozak AS, Russell S, et al. Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol. 2011;45:915-922.

How to cite this article: Xie H, Gao Y-M, Zhang Y-C, et al. Low let-7d exosomes from pulmonary vascular endothelial cells drive lung pericyte fibrosis through the TGFβR1/FoxM1/Smad/β-catenin pathway. J Cell Mol Med. 2020;24:13913-13926. https://doi.org/10.1111/jcmm.15989